GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Price-to-Owner-Earnings

Coherus BioSciences (FRA:8C5) Price-to-Owner-Earnings : (As of May. 21, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Price-to-Owner-Earnings?

As of today (2025-05-21), Coherus BioSciences's share price is €0.6988. Coherus BioSciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Coherus BioSciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Coherus BioSciences was 31.11. The lowest was 1.12. And the median was 16.53.


FRA:8C5's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 29.47
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-21), Coherus BioSciences's share price is €0.6988. Coherus BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.06. Therefore, Coherus BioSciences's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-21), Coherus BioSciences's share price is €0.6988. Coherus BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.07. Therefore, Coherus BioSciences's PE Ratio without NRI for today is At Loss.

During the past 13 years, Coherus BioSciences's highest PE Ratio without NRI was 18.93. The lowest was 0.00. And the median was 8.66.


Coherus BioSciences Price-to-Owner-Earnings Historical Data

The historical data trend for Coherus BioSciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Price-to-Owner-Earnings Chart

Coherus BioSciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.85

Coherus BioSciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.68 13.25 1.85 -

Competitive Comparison of Coherus BioSciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Coherus BioSciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Price-to-Owner-Earnings falls into.


;
;

Coherus BioSciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Coherus BioSciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.6988/-0.37
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coherus BioSciences  (FRA:8C5) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Coherus BioSciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Coherus BioSciences Headlines

No Headlines